Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | 18 Feb 2024 | |
Colonic Cancer | Preclinical | US | 18 Feb 2024 | |
Non-Small Cell Lung Cancer | Preclinical | US | 18 Feb 2024 | |
Pancreatic Cancer | Preclinical | US | 18 Feb 2024 | |
Stomach Cancer | Preclinical | US | 18 Feb 2024 |